C4 Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $6,152 | $11,016 | $11,230 | $6,463 |
Gross Profit | 4,351 | 11,016 | 11,230 | 6,463 |
EBITDA | -23,328 | -19,937 | -31,706 | -25,405 |
EBIT | -25,129 | -20,365 | -32,166 | -26,020 |
Net Income | -25,129 | -20,486 | -32,166 | -26,020 |
Net Change In Cash | 6,152 | 11,016 | 11,230 | 6,463 |
Free Cash Flow | -30,008 | -22,156 | -31,618 | -12,242 |
Cash | 61,274 | 74,603 | 58,809 | 78,157 |
Basic Shares | 126,074 | 116,784 | 72,563 | 71,005 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $35,947 | $35,584 | $20,756 | $31,096 |
Gross Profit | 27,972 | 35,584 | 13,019 | 31,096 |
EBITDA | -102,914 | -103,367 | -122,103 | -124,283 |
EBIT | -104,873 | -105,185 | -129,840 | -125,959 |
Net Income | -104,994 | -105,316 | -132,493 | -128,175 |
Net Change In Cash | 35,947 | 35,584 | 20,756 | 31,096 |
Cost of Revenue | -46,370 | |||
Free Cash Flow | -99,301 | -65,337 | -108,546 | -111,435 |
Cash | 74,603 | 55,499 | 126,590 | 29,754 |
Basic Shares | 82,894 | 69,372 | 49,640 | 48,861 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.20 |
2025-12-31 | -$0.18 |
2025-09-30 | -$0.44 |
2025-06-30 | -$0.37 |